(±)-10,5-(iminomethano)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene | 33759-85-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 二苯并环庚烯
• 英文名称: (±)-10,5-(iminomethano)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene
• 英文别名: (±)-10,5-(iminomethano)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene；10,11-dihydro-5,10-(iminomethano)-5H-dibenzo[a,d]-cycloheptene；10,5-(iminomethano)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene；16-Azatetracyclo[7.6.2.02,7.010,15]heptadeca-2,4,6,10,12,14-hexaene
• CAS: 33759-85-2
• 化学式: C₁₆H₁₅N
• 分子量: 221.302
• InChiKey: WJBGPJTZOSLZQG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  17
• 可旋转键数：
  0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• PHOTOREACTIVE REGULATOR OF GLUTAMATE RECEPTOR FUNCTION AND METHODS OF USE THEREOF
  申请人：Trauner Dirk

  公开号：US20090181454A1

  公开（公告）日：2009-07-16

  The present invention provides a synthetic regulator of glutamate receptor function, which regulator is a light-sensitive (photoreactive) regulator. The present invention further provides a light-regulated glutamate receptor that includes a subject synthetic regulator non-covalently associated with the glutamate receptor. Also provided are cells and membranes comprising a subject light-regulated glutamate receptor. The present invention further provides methods of modulating glutamate receptor function, involving use of light. The present invention further provides methods of identifying agents that modulate glutamate receptor function.

  本发明提供了一种合成的谷氨酸受体功能调节剂，该调节剂是一种光敏感（光反应性）调节剂。本发明还提供了一种光调节的谷氨酸受体，其中包括与谷氨酸受体非共价结合的主体合成调节剂。还提供了包括主体光调节谷氨酸受体的细胞和膜。本发明还提供了使用光调节谷氨酸受体的调节谷氨酸受体功能的方法。本发明还提供了识别调节谷氨酸受体功能的药剂的方法。
• Subtype-selective NMDA receptor ligands and the use thereof
  申请人：——

  公开号：US20010051633A1

  公开（公告）日：2001-12-13

  The invention relates to subtype-selective NMDA receptor ligands and the use thereof for treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the overstimulation of the excitatory amino acids, treating anxiety, psychosis, convulsions, aminoglycoside antibiotics-induced hearing loss, migraine headache, chronic pain, Parkinson's disease, glaucoma, CMV retinitis, urinary incontinence, opioid tolerance or withdrawal, and inducing anesthesia, as well as for enhancing cognition.

  本发明涉及亚型选择性NMDA受体配体及其用于治疗或预防与中风、缺血、中枢神经系统创伤、低血糖和手术相关的神经元丧失，以及治疗包括阿尔茨海默病、肌萎缩性侧索硬化症、亨廷顿病和唐氏综合症在内的神经退行性疾病，治疗或预防兴奋性氨基酸过度刺激的不良后果，治疗焦虑，精神病，惊厥，氨基糖苷类抗生素引起的听力损失，偏头痛，慢性疼痛，帕金森病，青光眼，巨细胞病毒性视网膜炎，尿失禁，阿片类耐受或戒断，并诱导麻醉，以及增强认知能力。
• New use of glutamate antagonists for the treatment of cancer
  申请人：Ikonomidou, Hrissanthi

  公开号：EP1002535A1

  公开（公告）日：2000-05-24

  New therapies can be devised based upon a demonstration of the role of glutamate in the pathogenesis of cancer. Inhibitors of the interaction of glutamate with the AMPA, kainate, or NMDA receptor complexes are likely to be useful in treating cancer and can be formulated as pharmaceutical compositions. They can be identified by appropriate screens.

  根据谷氨酸在癌症发病机制中的作用，可以设计出新的疗法。谷氨酸与 AMPA、kainate 或 NMDA 受体复合物相互作用的抑制剂可能有助于治疗癌症，并可配制成药物组合物。它们可以通过适当的筛选来确定。
• Methods of treatment of eye trauma and disorders
  申请人：——

  公开号：US20030027801A1

  公开（公告）日：2003-02-06

  Methods are provided for treatment of eye disorders and injury, including methods for treatment of reduced flow of blood or other nutrients to retinal tissue and/or optic nerve, methods for treatment of retinal ischemia and trauma and methods for treatment for optic nerve injury/damage.

  提供了治疗眼部疾病和损伤的方法，包括治疗流向视网膜组织和/或视神经的血液或其他营养物质减少的方法、治疗视网膜缺血和创伤的方法以及治疗视神经损伤/损坏的方法。
• Use of glutamate antagonists for the treatment of cancer
  申请人：Ikonomidou Hrissanthi

  公开号：US20050054619A1

  公开（公告）日：2005-03-10

  Disclosed are methods for treating cancer by administering an inhibitor of the interaction of glutamate with the KA receptor complex.

  所公开的是通过施用谷氨酸与 KA 受体复合物相互作用的抑制剂来治疗癌症的方法。